Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 18, 2026

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
10:09

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound

Published on: August 4, 2022

Vascular access outcomes and medication use: a USRDS study.

Alexander S Yevzlin1, Emily L Conley, Robert J Sanchez

  • 1School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin 53713, USA. asy@medicine.wisc.edu

Seminars in Dialysis
|December 8, 2006
PubMed
Summary

Certain antiplatelet medications, like ticlopidine, dipyridamole, and aspirin, were linked to worse hemodialysis vascular access patency. This study found no clear medication benefits for access longevity in hemodialysis patients.

Related Concept Videos

Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and demographic profiles of people not meeting LDL-C goals after treatment with a proprotein convertase subtilisin/kexin type 9 inhibitor.

American journal of preventive cardiology·2026
Same author

Effects of Aliskiren Monotherapy on Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Blood Pressure and Urinary Protein Excretion Outcomes.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same author

Content Validation of the Flares Diary: A Qualitative Analysis of the Flares Experience Within the Fibrodysplasia Ossificans Progressiva (FOP) Population.

Advances in therapy·2026
Same author

From Pen to Prompt: Navigating LLM-Generated Content in Postgraduate Pharmacy Training Applications.

American journal of pharmaceutical education·2026
Same author

Improving Access to HIV Prevention Services in Community Pharmacies in the US Southeast: Protocol for a Hybrid Type 1 Effectiveness-Implementation Study.

JMIR research protocols·2025
Same author

The impact of electronic health messaging on diagnosis of familial hypercholesterolemia and management of patients with LDL-C ≥190 mg/dL.

Journal of clinical lipidology·2025

Area of Science:

  • Nephrology
  • Vascular Surgery
  • Pharmacology

Background:

  • Medications are explored to improve hemodialysis vascular access outcomes.
  • Anticoagulant, antiplatelet, and pleiotropic properties are considered.
  • Vascular access patency is crucial for effective hemodialysis.

Purpose of the Study:

  • To evaluate the relationship between medication use and vascular access patency in hemodialysis patients.
  • To identify if specific medications impact the longevity of vascular access.
  • To analyze medication effects on arteriovenous fistula, PTFE graft, and catheter patency.

Main Methods:

  • Historical cohort study using the US Renal Data System Dialysis Mortality and Morbidity Wave II study.
  • Included patients with arteriovenous fistula, PTFE graft, or permanent catheter.

Related Experiment Videos

Last Updated: Jul 18, 2026

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
10:09

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound

Published on: August 4, 2022

  • Cox regression analysis adjusted for demographic and clinical factors to model access failure.

    • Main Results:

    • Antiplatelet medications (ticlopidine, dipyridamole, aspirin) were associated with significantly worse arteriovenous fistula patency.
    • PTFE graft patency showed better outcomes in males and older individuals.
    • No beneficial effect of specific medications on overall access patency was identified.

    Conclusions:

    • Antiplatelet agents demonstrated a significant negative association with hemodialysis vascular access patency.
    • Findings contrast with some published data, highlighting potential risks of certain antiplatelet drugs.
    • Further research is needed to clarify medication impacts on vascular access longevity.